Eisai Company Description
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer.
The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate; and a clinical trial collaboration and supply agreement with Medivir for the evaluation of fostrox, a liver-targeted treatment.
Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955.
Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1941 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 11,067 |
| CEO | Haruo Naito |
Contact Details
Address: 4-6-10, Koishikawa Tokyo, 112-8088 Japan | |
| Phone | 81 3 3817 3700 |
| Website | eisai.co.jp |
Stock Details
| Ticker Symbol | ESALF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3160400002 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Haruo Naito | Chief Executive Officer, Representative Corporate Officer and Director |
| Gary Hendler | Senior Vice President and President of EMEA Region |
| Dr. Lynn D. Kramer FAAN, M.D. | Vice President and Chief Clinical Officer |
| Yanhui Feng | Senior Vice President |
| Mitsuru Shomon | Vice President and Chief Financial Officer |
| Keisuke Naito | Representative Corporate Officer, EVice President, Chief Operating Officer and Chief Growth Officer |
| Makoto Hoketsu | Vice President and Chief Information Officer |
| Masatomi Akana | Senior Vice President, Chief Government Relations Officer and Chief IR Officer |
| Shin Kato | Vice President, General Counsel and Chief Compliance Officer |
| Sayoko Sasaki | Vice President of Corporate Communications and Sustainability |